# Tesamorelin: The One Compound With a Real Dossier > Tesamorelin: Research Overview — Clean Peptides Lab — A cited literature summary of tesamorelin, the only FDA-approved peptide on this desk. Covers mechanism, the pivotal HIV-lipodystrophy trials, a 2026 meta-analysis, and regulatory-grade quality status. **03 / Tesamorelin** A 44-amino-acid growth-hormone-releasing hormone analogue, FDA-approved since 2010 for a specific indication — and the clearest example on this desk of what regulatory-grade quality control actually looks like. ## The short version Tesamorelin is a lab-made version of a natural signaling hormone, growth-hormone-releasing hormone (GHRH), engineered to resist rapid breakdown in the bloodstream. It is the one compound on this desk with an actual FDA approval: since 2010 it has been indicated to reduce excess abdominal fat in people with HIV-associated lipodystrophy, a fat-redistribution condition linked to antiretroviral therapy. The trial record is unusually deep for a peptide. A 2026 meta-analysis pooling five randomized controlled trials found tesamorelin reduced visceral fat by an average of about 27.7 cubic centimeters and liver fat by roughly 4.3 percentage points, without a significant increase in serious side effects [13]. That approval status also means tesamorelin, unlike the other two compounds on this hub, is manufactured under pharmaceutical-grade quality control when sold as the approved product — a genuinely different quality standard from a research-grade vial, and the clearest illustration of what "lab-grade" is supposed to mean but rarely does in this market. ## What it is Tesamorelin is a synthetic 44-amino-acid analogue of human GHRH(1-44), with a chemical group called trans-3-hexenoic acid attached to its front end. That modification blocks a blood enzyme, dipeptidyl peptidase-IV (DPP-IV), that would otherwise rapidly degrade the native hormone, extending tesamorelin's stability in plasma well beyond that of unmodified GHRH. It is supplied clinically as tesamorelin acetate, with the free-base molecule carrying the formula C221H366N72O67S. Because it is an approved prescription drug, tesamorelin's manufacturing is subject to FDA oversight — batch consistency, identity confirmation and purity testing are regulatory requirements, not optional marketing claims. Research-grade tesamorelin sold outside that pharmaceutical supply chain does not carry the same assurance, even when a vendor's certificate of analysis reports a high purity percentage. ## How it works Tesamorelin binds the growth-hormone-releasing hormone receptor on pituitary cells called somatotrophs, activating an internal signaling cascade that stimulates the body's own pulsatile release of growth hormone. That growth hormone, in turn, drives the liver to produce insulin-like growth factor-1 (IGF-1), and the combination of GH and IGF-1 promotes fat breakdown — lipolysis — with a documented preference for visceral fat, the metabolically active fat that surrounds internal organs, over fat stored elsewhere. Because tesamorelin amplifies the body's own natural GH rhythm rather than supplying growth hormone directly, its metabolic profile differs somewhat from recombinant human growth hormone therapy. In a small trial of 13 healthy men, two weeks of tesamorelin raised mean overnight growth hormone and substantially increased IGF-1, while leaving both fasting glucose and insulin-stimulated glucose uptake statistically unchanged — an early signal that its GH-axis effect does not automatically translate into a measurable glucose problem, at least over that short a window [16]. ## What the research shows The most current evidence is a 2026 meta-analysis pooling five randomized controlled trials in HIV-associated lipodystrophy. It found tesamorelin reduced visceral adipose tissue by a mean difference of 27.71 square centimeters (95% confidence interval, 17.06 to 38.37; P<0.001), trunk fat by 1.18 kilograms, and hepatic (liver) fat fraction by 4.28 percentage points, while increasing lean body mass by 1.42 kilograms — all statistically significant, with no serious adverse events attributed to treatment [13]. The pivotal JAMA trial that helped establish the visceral-fat effect randomized 50 antiretroviral-treated adults with HIV to tesamorelin 2 milligrams daily or placebo for six months. The treatment effect on visceral fat was -42 square centimeters (P=0.005), with a net reduction in hepatic lipid content of 2.9 percentage points (P=0.003) [15]. A longer, 52-week program spanning 273 people on tesamorelin versus 137 on placebo found the visceral-fat reduction sustained at roughly 18% below baseline (P<0.001) — but fat reaccumulated once treatment stopped, and glucose-related lab changes over the full year were not judged clinically significant [17]. On the safety side, the NIH's LiverTox monograph — a drug-safety reference maintained by the National Institute of Diabetes and Digestive and Kidney Diseases — assigns tesamorelin a likelihood score of E, meaning it is an unlikely cause of clinically apparent liver injury, with no attributable liver-injury cases and no unexplained liver-enzyme elevations reported across its trial program [14]. ## Reported effects, cautions & safety Tesamorelin's own signed research corpus does not include a structured set of community-reported (anecdotal) effects for this compound, so this section stays with what the clinical literature documents directly rather than filling the gap with unsourced anecdote. *Cited cautions from the trial and regulatory literature:* - **Approval is narrow.** Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy; using it for general visceral-fat reduction, anti-aging or any other purpose outside that labeled indication is off-label and outside the population the pivotal trials actually studied [15][17]. - **Benefits are contingent on continued use.** The 52-week program found visceral fat began reaccumulating once treatment was discontinued, meaning tesamorelin's effect is not a one-time or permanent change [17]. - **It raises IGF-1, a growth factor.** No excess cancer signal appeared across the trial program, but active malignancy is treated as a contraindication in tesamorelin's labeling given IGF-1's general role as a growth signal [13][15]. - **Glucose effects appear modest but should not be assumed absent.** A small early study found no significant change in fasting glucose or insulin sensitivity over two weeks [16], and the 52-week program found no clinically significant glucose change overall [17], but the compound's mechanism runs through the growth-hormone axis, which is generally associated with reduced insulin sensitivity at high or sustained exposure — a reason monitoring is still standard practice in people with dysglycemia. - **Population studied is narrow.** The pivotal trials enrolled HIV-positive adults on antiretroviral therapy; how well the visceral-fat findings generalize to people without HIV is mechanistically plausible but not established by the large randomized trials cited here. ## Where it fits in lab-grade standards Tesamorelin is the anchor case for this hub's framing question. As an FDA-approved drug, the tesamorelin sold by prescription is manufactured to a pharmaceutical standard — identity, purity and batch consistency verified as a condition of approval, not offered as a marketing claim. That is a materially different guarantee than a research-grade vial from an unregulated supplier, even one carrying a chromatography certificate reporting a high purity percentage, because a certificate speaks only to that one batch on the day it was tested and carries none of the ongoing regulatory oversight behind an approved product. Reading tesamorelin next to [GHK-Cu](/ghk-cu) and [ipamorelin](/ipamorelin) on the [comparison page](/compare) makes that gap concrete — three compounds, three very different relationships between what a supplier calls "lab-grade" and what the term can actually be shown to mean. --- Clean Peptides Lab reads the purity, testing and quality-signal literature on GHK-Cu, ipamorelin and tesamorelin; it runs no assays, holds no certification, and is a reading desk, not a laboratory.